Bioadhesive drug formulations for oral transmucosal delivery
AssigneeAcelRx Pharmaceuticals, Inc.
InventorsStelios Tzannis, Larry Hamel, Pamela Palmer, Thomas Schreck, Andrew I. Poutiatine
Life of this patent
Estimating the term…
Abstract
Bioadhesive drug formulations that adhere to an oral mucosal membrane of a subject are provided together with single dose applicators and devices for delivering the drug formulations to the oral mucosa, and methods for using the same.
Claims27
1-92. (canceled)
A method of treating pain in a subject, comprising administering a bioadhesive tablet to the oral mucosa of a subject,
- wherein said tablet comprises:
- (a) from about 2.5 to about 100 micrograms of sufentanil, expressed as the base;
- and
- (b) a bioadhesive material, wherein said bioadhesive material provides for adherence to the oral mucosa of said subject, and
- (c) said tablet has a volume of from about 0.1 microliters to about 50 microliters,
- wherein after administration of said tablet to said subject, said tablet provides a minimal saliva response and minimal swallowing of sufentanil;
- and more than 50% of drug delivery of sufentanil occurs via the oral transmucosal route.
The method according to claim 1, wherein said tablet is administered using a drug dispensing device, wherein said drug dispensing device is effective to check user identification and provide a lockout period between dose dispenses.
Dependencies are inferred from the claim text.